Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impac...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/3/442 |
| _version_ | 1797560114037653504 |
|---|---|
| author | Lorna Leal Csaba Fehér Valèria Richart Berta Torres Felipe García |
| author_facet | Lorna Leal Csaba Fehér Valèria Richart Berta Torres Felipe García |
| author_sort | Lorna Leal |
| collection | DOAJ |
| description | A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials. |
| first_indexed | 2024-03-10T17:54:50Z |
| format | Article |
| id | doaj.art-5f8026c585eb4a81a23e26d10c75814b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T17:54:50Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-5f8026c585eb4a81a23e26d10c75814b2023-11-20T09:13:23ZengMDPI AGVaccines2076-393X2020-08-018344210.3390/vaccines8030442Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological ResponseLorna Leal0Csaba Fehér1Valèria Richart2Berta Torres3Felipe García4Infectious Diseases Department—HIV Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Department—HIV Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Department—HIV Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Department—HIV Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Department—HIV Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainA functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials.https://www.mdpi.com/2076-393X/8/3/442antiretroviral therapy interruptionATIHIV-1surrogate markersresponse |
| spellingShingle | Lorna Leal Csaba Fehér Valèria Richart Berta Torres Felipe García Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response Vaccines antiretroviral therapy interruption ATI HIV-1 surrogate markers response |
| title | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
| title_full | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
| title_fullStr | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
| title_full_unstemmed | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
| title_short | Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response |
| title_sort | antiretroviral therapy interruption ati in hiv 1 infected patients participating in therapeutic vaccine trials surrogate markers of virological response |
| topic | antiretroviral therapy interruption ATI HIV-1 surrogate markers response |
| url | https://www.mdpi.com/2076-393X/8/3/442 |
| work_keys_str_mv | AT lornaleal antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT csabafeher antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT valeriarichart antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT bertatorres antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse AT felipegarcia antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse |